|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
|
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Current assets | |||||||||
| Cash | |||||||||
| Other receivable | |||||||||
| Due from Sponsor | |||||||||
| Short-term prepaid insurance | |||||||||
| Prepaid expenses | |||||||||
| Total current assets | |||||||||
| Deferred offering costs | |||||||||
| Long-term prepaid insurance | |||||||||
| Assets held in trust account | |||||||||
| TOTAL ASSETS | |||||||||
| LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS’ DEFICIT | |||||||||
| Current liabilities | |||||||||
| Accrued offering costs | |||||||||
| Accrued expenses | |||||||||
| Promissory note - related party | |||||||||
| Working Capital Note | |||||||||
| Working Capital Note - related party, net of debt discount | |||||||||
| Accrued interest payable | |||||||||
| Total current liabilities | |||||||||
| Deferred underwriting fee payable | |||||||||
| Deferred Fee payable | |||||||||
| Total Liabilities | |||||||||
| Class A Ordinary Shares subject to possible redemption, 23,000,000 shares at redemption value of approximately $10.86 and $10.67 per share as of June 30, 2026 and December 31, 2025, respectively | |||||||||
| Shareholders’ Deficit | |||||||||
| Ordinary shares, value | |||||||||
| Additional paid-in capital | |||||||||
| Accumulated deficit | |||||||||
| Total Shareholders’ Deficit | |||||||||
| TOTAL LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS’ DEFICIT |
Loading...
